Modification of the COVID-19 Vaccine Response by an Intervention on the Intestinal Flora

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

592 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-10

Study Completion Date

2024-07-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The elderly, who are often in poorer health, have been particularly affected by the COVID-19 pandemic. Recent study results show that while vaccines have been very effective in the short term, protection for the elderly may not be sufficient 6 months after the 2nd dose. Some countries have started to offer a 3rd dose. We are considering acting on the intestinal flora of the elderly (which is often unbalanced) in order to increase the effectiveness of the vaccination. Indeed, it has been demonstrated that probiotics (which can rebalance the intestinal flora) significantly increase the production of antibodies after vaccination against the flu virus. Our hypothesis is that taking probiotics one month before and one month after the 4th dose of COVID vaccine would result in longer lasting vaccine protection in seniors. This study will include 688 seniors, aged 65-89 years, who have not had COVID-19, who have received 3 doses of an mRNA vaccine and who will accept a another booster dose . All participants will take 1 capsule/day (probiotics or placebo) for 1 month and in the middle of this period will receive a booster dose. On 3 occasions (inclusion, 3 months and 6 months post-vaccination), they will prick their fingertip and express the drop of blood on a blotting paper. They will mail this dried blood sample in an envelope for antibody testing in Quebec Research center. A subgroup of 100 participants willing to travel at CHUS' Clinical Research Center for 2 times (inclusion visit and final visit) will be invited to do a blood test. The investigators expect to reduce the number of seniors who are poorly protected by a booster dose 6 months after the injection. If successful, this approach could quickly be implemented worldwide as probiotics have few side effects and are affordable.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination

NCT05157425

Influenza Vaccine

COMPLETED NA

WHO COVID-19 - Evaluation of the Efficacy of Probiotics to Reduce the Occurrence of Long COVID

NCT05080244

COVID-19

COMPLETED NA

Probiotics and Influenza Vaccination Response

NCT05690373

Vaccine Response

COMPLETED NA

Probiotic, Prebiotic and Synbiotic Effect on Immunity

NCT01084434

Dietary Intervention

UNKNOWN NA

Evaluation of a Probiotic Supplementation in the Immune Response of Participants With COVID-19 (Coronavirus Disease).

NCT04937556

Covid19

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The elderly are at high risk of morbidity and mortality from COVID-19. They are particularly targeted by recent data: i) faster decline of the immune response in the elderly and ii) increase of COVID infection 6 months after the 2nd dose of vaccine. In addition, they often have an imbalance of the microbiota that plays a key role in the activation of the immune system. Taking probiotics, which improve the microbiota, could increase the vaccine response of the elderly. Indeed, it has been shown in 2 meta-analyses that probiotics improve immune response after influenza vaccination. The investigators believe that probiotics taken at the time of 4th dose (booster dose) of vaccine could improve immune memory: i) humoral (cellular Receptor-Binding Domain antibody) and ii) (B lymphocytes, CD4+ T and CD8+ T), in the medium term and would then allow a greater spacing of the booster doses in the future OBJECTIVE: To reduce by 33% the percentage of elders without RBD antibodies, 6 months after the booster dose of vaccine, by taking 2 strains of probiotics compared to placebo. Secondary objectives: To improve the evolution of RBD Ac by longitudinal analysis at 5 different time points (inclusion, vaccination, 1 month, 3 months, and 6 months post-vaccination).- To compare the evolution of neutralizing Ac and memory B, CD4+ T, and CD8+ T cells, at inclusion and 6 months post-vaccination. METHODOLOGYDesign. A randomized, intention-to-treat, blinded, placebo-controlled trial.Investigation products are: for the intervention group, a capsule with 2 strains of probiotics and for control group or a placebo capsule. Participants will take one capsule per day for 30 days (15 d and 15 d after the booster dose of vaccine). Both vaccines (Pfizer-BioNTech, Moderna) may be used depending on availability and state of knowledge . With 1:1 allocation, via the REDCap application, using permuted blocks and stratified according to randomization.gender, age (65-79 and 80-89 years) and vaccine type for the booster dose. Inclusion criteria: (Pfizer-BioNTech or Moderna) for more than 6 months, volunteers for booster dose of vaccine, telephone or internet access, informed consent, and living \<75 km from CRC (only for participants for blood test visits). Exclusion criteria: patients with allergies (soy...), COVID-19 disease, possibly affected cognitive functions, chronically weakened immune system (AIDS...) or undergoing anti-cancer treatment. Five finger-prick dried blood samples (DBS) are planned (inclusion, vaccination, 1, 3 and 6 months post-vaccination).The DBS will be mailed to Quebec City . A telephone or mail follow up will be realised for each participant. A subgroup of 100 participants willing to travel will be invited to visit us at the inclusion and final visit to do a blood test. Fecal self-sampling (inclusion) for microbiota study will be sent to I Laforest-Lapointe's laboratory. The levels of RBD Ac and N Ac will be determined by a validated Elisa test (3 time points). From the venous blood samples (inclusion and 6 months post-vaccination),we will be studied: i) the pseudotyped viral neutralization and ii) the cellular immune memory in flow cytometry (B, T CD4+ and T CD8+ lymphocytes). With 30% undetectable RBD Ac in the placebo group (6 months post-vaccine) and 20% in the intervention group, are required (15% attrition, 80% power, 5% two-sided test). The 688 subjects primary analysis on the dichotomous criterion (Ac RBD) will use a GMM logistic regression model for longitudinal data with covariate variant/time.PROJECT OUTCOMEImproving vaccination and spacing vaccine doses among the elderly are major public health issues. If successful, probiotics could be used worldwide very quickly. They have few side effects, are available over the counter and are affordable.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Vaccine Reaction Elderly

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotics

taking a capsule containing the probiotics 15 d before and 15 d after booster shot.

Group Type EXPERIMENTAL

Taking capsule containing probiotics or placebo

Intervention Type DIETARY_SUPPLEMENT

The probiotics capsule containing two strains of probiotics.

Control

taking a capsule containing a placebo 15 d before and 15 d after booster shot.

Group Type PLACEBO_COMPARATOR

Taking capsule containing probiotics or placebo

Intervention Type DIETARY_SUPPLEMENT

The probiotics capsule containing two strains of probiotics.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Taking capsule containing probiotics or placebo

The probiotics capsule containing two strains of probiotics.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women
* aged 65-89 years
* who have received 3 doses of a mRNA vaccine (Pfizer-BioNTech or Moderna) for more than 6 months;
* volunteered for a booster dose
* had telephone or internet access
* were able to provide informed consent
* lived \<75 km from the CRC (subgroup of 100 participants only)

Exclusion Criteria

* Patients with COVID-19 disease (clinical and serological data at post);
* with possibly affected cognitive functions (score \< 12 on the Functional Activities Questionnaire (FAQ))
* with allergies (soy, lactose, yeast, maltodextrin)
* with a chronically weakened immune system (AIDS...)
* undergoing anti-cancer treatment (chemotherapy or radiotherapy)
* who do not speak French or English.

Minimum Eligible Age

65 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes